Novel endomorphin analogues with antagonist activity at the mu-opioid receptor in the gastrointestinal tract

Regulatory Peptides

Volumn 162, Issue 1-3, 2010, Pages 109-114

  Fichna, Jakub ^a,b   Gach, Katarzyna ^b   Perlikowska, Renata ^b   Cravezic, Aurore ^c   Bonnet, Jean Jacques ^c   do Rego, Jean Claude ^c,d   Janecka, Anna ^b   Storr, Martin A ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

^c UNIVERSITÉ DE ROUEN   (France)

^d CNRS   (France)

Author keywords

Endogenous opioid peptide; Mouse gastrointestinal tract; Peripherally restricted MOR antagonist; Smooth muscle strips

Indexed keywords

ANTANAL 1; ANTANAL 2; ANTANAL 2A; BETA FUNALTREXAMINE; ENDOMORPHIN 2; LOPERAMIDE; MORPHINE; MU OPIATE RECEPTOR ANTAGONIST; NALOXONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG PENETRATION; DRUG SELECTIVITY; ENZYME DEGRADATION; GASTROINTESTINAL TRACT; HOT PLATE TEST; INTESTINE CONTRACTION; INTESTINE MOTILITY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; BLOOD-BRAIN BARRIER; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL TRACT; MALE; MICE; OLIGOPEPTIDES; RECEPTORS, OPIOID, MU;

MUS;

EID: 77952668263     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.regpep.2010.01.001     Document Type: Article

References (34)

1. Montagnini M.L., Zaleon C.R. Pharmacological management of cancer pain. J Opioid Manag 2009, 5:89-96.
2. Christo P.J., Mazloomdoost D. Cancer pain and analgesia. Ann N Y Acad Sci 2008, 1138:278-298.
3. McCleane G., Smith H.S. Opioids for persistent noncancer pain. Med Clin North Am 2007, 91:177-197.
4. Kanjhan R. Opioids and pain. Clin Exp Pharmacol Physiol 1995, 22:397-403.
5. Sawynok J. Topical and peripherally acting analgesics. Pharmacol Rev 2003, 55:1-20.
6. Lehmann K.A. Opioids: overview on action, interaction and toxicity. Support Care Cancer 1997, 5:439-444.
7. Swegle J.M., Logemann C. Management of common opioid-induced adverse effects. Am Fam Physician 2006, 74:1347-1354.
8. Vanegas G., Ripamonti C., Sbanotto A., De Conno F. Side effects of morphine administration in cancer patients. Cancer Nurs 1998, 21:289-297.
9. Dehaven-Hudkins D.L., DeHaven R.N., Little P.J., Techner L.M. The involvement of the mu-opioid receptor in gastrointestinal pathophysiology: therapeutic opportunities for antagonism at this receptor. Pharmacol Ther 2008, 117:162-187.
10. Kurz A., Sessler D.I. Opioid-induced bowel dysfunction: pathophysiology and potential new therapies. Drugs 2003, 63:649-671.
11. Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg 2001, 182:11S-18S.
12. Tamayo A.C., az-Zuluaga P.A. Management of opioid-induced bowel dysfunction in cancer patients. Support Care Cancer 2004, 12:613-618.
13. Holzer P., Ahmedzai S.H., Niederle N., Leyendecker P., Hopp M., Bosse B., Spohr I., Reimer K. Opioid-induced bowel dysfunction in cancer-related pain: causes, consequences, and a novel approach for its management. J Opioid Manag 2009, 5:145-151.
14. Chang H.Y., Kelly E.C., Lembo A.J. Current gut-directed therapies for irritable bowel syndrome. Curr Treat Options Gastroenterol 2006, 9:314-323.
15. Culpepper-Morgan J.A., Inturrisi C.E., Portenoy R.K., Foley K., Houde R.W., Marsh F., Kreek M.J. Treatment of opioid-induced constipation with oral naloxone: a pilot study. Clin Pharmacol Ther 1992, 52:90-95.
16. Schmidt W.K. Alvimopan (ADL 8-2698) is a novel peripheral opioid antagonist. Am J Surg 2001, 182:27S-38S.
17. Shaiova L., Rim F., Friedman D., Jahdi M. A review of methylnaltrexone, a peripheral opioid receptor antagonist, and its role in opioid-induced constipation. Palliat Support Care 2007, 5:161-166.
18. Greenwood-Van Meerveld B., Gardner C.J., Little P.J., Hicks G.A., Dehaven-Hudkins D.L. Preclinical studies of opioids and opioid antagonists on gastrointestinal function. Neurogastroenterol Motil 2004, 16:46-53.
19. Camilleri M. New therapeutic approaches in irritable bowel syndrome. Eur Rev Med Pharmacol Sci 2008, 12:139-140.
20. Fichna J., do-Rego J.C., Chung N.N., Lemieux C., Schiller P.W., Poels J., Vanden Broeck J., Costentin J., Janecka A. Synthesis and characterization of potent and selective mu-opioid receptor antagonists, [Dmt(1), D-2-Nal(4)]endomorphin-1 (Antanal-1) and [Dmt(1), D-2-Nal(4)]endomorphin-2 (Antanal-2). J Med Chem 2007, 50:512-520.
21. Fichna J., DoRego J.C., Janecki T., Staniszewska R., Poels J., Poels J., Vanden Broeck J., Costentin J., Schiller P.W., Janecka A. Novel highly potent mu-opioid receptor antagonist based on endomorphin-2 structure. Bioorg Med Chem Lett 2008, 18:1350-1353.
22. Fichna J., Schicho R., Andrews C.N., Bashashati M., Klompus M., McKay D.M., Sharkey K.A., Zjawiony J.K., Janecka A., Storr M. Salvinorin A inhibits colonic transit and neurogenic ion transport in mice by activating kappa-opioid and cannabinoid receptors. Neurogastroenterol Motil 2009, 21:1326-e128.
23. Janecka A., Kruszynski R., Fichna J., Kosson P., Janecki T. Enzymatic degradation studies of endomorphin-2 and its analogs containing N-methylated amino acids. Peptides 2006, 27:131-135.
24. Haley T.J., McCormick W.G. Pharmacological effects produced by intracerebral injection of drugs in the conscious mouse. Br J Pharmacol Chemother 1957, 12:12-15.
25. Eddy N.B., Leimbach D. Synthetic analgesics. II. Dithienylbutenyl- and dithienylbutylamines. J Pharmacol Exp Ther 1953, 107:385-393.
26. Awouters F., Megens A., Verlinden M., Schuurkes J., Niemegeers C., Janssen P.A. Loperamide. Survey of studies on mechanism of its antidiarrheal activity. Dig Dis Sci 1993, 38:977-995.
27. Janecka A., Staniszewska R., Gach K., Fichna J. Enzymatic degradation of endomorphins. Peptides 2008, 29:2066-2073.
28. Tonini M., Fiori E., Balestra B., Spelta V., D'Agostino G., Di Nucci A., Brecha N.C., Sternini C. Endomorphin-1 and endomorphin-2 activate mu-opioid receptors in myenteric neurons of the guinea-pig small intestine. Naunyn Schmiedebergs Arch Pharmacol 1998, 358:686-689.
29. Storr M., Hahn A., Gaffal E., Saur D., Allescher H.D. Effects of endomorphin-1 and -2 on mu-opioid receptors in myenteric neurons and in the peristaltic reflex in rat small intestine. Clin Exp Pharmacol Physiol 2002, 29:428-434.
30. Yu Y., Cui Y., Wang X., Lai L.H., Wang C.L., Fan Y.Z., Liu J., Wang R. In vitro characterization of the effects of endomorphin 1 and 2, endogenous ligands for mu-opioid receptors, on mouse colonic motility. Biochem Pharmacol 2007, 73:1384-1393.
31. Banta C.A., Clemens E.T., Krinsky M.M., Sheffy B.E. Sites of organic acid production and patterns of digesta movement in the gastrointestinal tract of dogs. J Nutr 1979, 109:1592-1600.
32. Arhan P., Devroede G., Jehannin B., Lanza M., Faverdin C., Dornic C., Persoz B., Tetreault L., Perey B., Pellerin D. Segmental colonic transit time. Dis Colon Rectum 1981, 24:625-629.
33. Becker G., Galandi D., Blum H.E. Peripherally acting opioid antagonists in the treatment of opiate-related constipation: a systematic review. J Pain Symptom Manage 2007, 34:547-565.
34. Saad R.J., Chey W.D. Recent developments in the therapy of irritable bowel syndrome. Expert Opin Investig Drugs 2008, 17:117-130.